A new bioassay for human growth hormone based on incorporation of labelled proline into skin.
An in-vitro bioassay for human growth hormone (hGH) has been developed, based on the dose-related enhancement of radioactivity in skin of hypophysectomized rats given daily s.c. injections of hGH and a single i.p. injection of labelled proline. The measured radioactivity, taken as the response, was shown to be independent of the site at which the skin was sampled. Valid dose-response relationships were obtained after as little as 3 days of treatment with GH. The assays by this method are shown to be more precise than the widely used weight-gain and tibial-width bioassays. Assays carried out gave an average index of precision of 0.036.